Incidence and Result of Treatment-Demanding Retinopathy of Prematurity Using Revised U.S. Screening Guidelines

Abstract

Objective To study the incidence of treated retinopathy of prematurity (ROP) using the revised U.S. screening guidelines, the rate of missed treatment, and unfavorable anatomic outcomes over a period of 2 years.

Study Design We reviewed the admission records of premature patients treated at our hospital from September 2008 to August 2010. Any baby born with a gestational age (GA) of less than 30 weeks or a birth body weight (BW) of less than 2000 g was included in this study. The ROP screening followed the revised U.S. screening guidelines as presented in 2006. The indications of treatment for ROP were threshold disease as defined by the Multicenter Trial of Cryotherapy for Retinopathy of Prematurity study and type 1 prethreshold ROP as defined by the Early Treatment for Retinopathy of Prematurity Randomized Trial study.

Results There were 385 infants who were examined for ROP screening during this period. Nineteen babies (35 eyes) fit the treatment criteria and received treatment. The incidence of treatment-demand ROP was 4.9% (19/385). Four babies had a birth BW >1500 g (4/19; 21%). Seventeen babies received treatment during their first admission and two babies received treatment during outpatient follow-up. No baby missed timely treatment. Three eyes progressed to stage 4/5 after receiving intravitreal bevacizumab treatment. The success rate after primary bevacizumab was 91% (30/33 eyes).

Conclusion The incidence of treatment-demanding ROP using revised U.S. screening criteria was 4.9%. Teamwork and cooperation are very important to ensure that the highest-quality care possible is provided to patients in a timely manner.

Keywords

retinopathy of prematurity - screening programs and criteria - gestational age - birth body weight

• References

• 1 Gilbert C, Fielder A, Gordillo L , et al; International NO-ROP Group. Characteristics of infants with severe retinopathy of prematurity in countries with low, moderate, and high levels of development: implications for screening programs. Pediatrics 2005; 115: e518-e525
• 2 Azad R, Chandra P, Patwardhan SD, Gupta A. Importance of the “third criterion” for retinopathy of prematurity screening in developing countries. J Pediatr Ophthalmol Strabismus 2009; 46: 332-334 ; quiz 335–336
• 3 Başmak H, Niyaz L, Sahin A, Erol N, Gürsoy HH. Retinopathy of prematurity: screening guidelines need to be reevaluated for developing countries. Eur J Ophthalmol 2010; 20: 752-755
• 4 Section on Ophthalmology American Academy of Pediatrics; American Academy of Ophthalmology; American Association for Pediatric Ophthalmology and Strabismus. Screening examination of premature infants for retinopathy of prematurity. Pediatrics 2006; 117: 572-576
• 5 Retinopathy of prematurity: guidelines for screening and treatment. The report of a Joint Working Party of The Royal College of Ophthalmologists and the British Association of Perinatal Medicine. Early Hum Dev 1996; 46: 239-258
• 6 Ugurbas SC, Gulcan H, Canan H, Ankarali H, Torer B, Akova YA. Comparison of UK and US screening criteria for detection of retinopathy of prematurity in a developing nation. J AAPOS 2010; 14: 506-510
• 7 Yang MB, Donovan EF. Risk analysis and an alternative protocol for reduction of screening for retinopathy of prematurity. J AAPOS 2009; 13: 539-545
• 8 Zin AA, Moreira MEL, Bunce C, Darlow BA, Gilbert CE. Retinopathy of prematurity in 7 neonatal units in Rio de Janeiro: screening criteria and workload implications. Pediatrics 2010; 126: e410-e417
• 9 Slidsborg C, Forman JL, Rasmussen S , et al. A new risk-based screening criterion for treatment-demanding retinopathy of prematurity in Denmark. Pediatrics 2011; 127: e598-e606
• 10 Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity. Preliminary results. Arch Ophthalmol 1988; 106: 471-479
• 11 Early Treatment For Retinopathy Of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol 2003; 121: 1684-1694
• 12 Screening examination of premature infants for retinopathy of prematurity. A joint statement of the American Academy of Pediatric, the American Association for Pediatric Ophthalmology and Strabismus, and the American Academy of Ophthalmology. Ophthalmology 1997; 104: 888-889
• 13 American Academy of Pediatrics. Section on Ophthalmology. Screening examination of premature infants for retinopathy of prematurity. Pediatrics 2001; 108: 809-811
• 14 International Committee for the Classification of Retinopathy of Prematurity. The International Classification of Retinopathy of Prematurity revisited. Arch Ophthalmol 2005; 123: 991-999
• 15 Wu WC, Yeh PT, Chen SN, Yang CM, Lai CC, Kuo HK. Effects and complications of bevacizumab use in patients with retinopathy of prematurity: a multicenter study in Taiwan. Ophthalmology 2011; 118: 176-183
• 16 Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter Trial of Cryotherapy for Retinopathy of Prematurity: ophthalmological outcomes at 10 years. Arch Ophthalmol 2001; 119: 1110-1118
• 17 Good WV, Hardy RJ, Dobson V , et al; Early Treatment for Retinopathy of Prematurity Cooperative Group. Final visual acuity results in the early treatment for retinopathy of prematurity study. Arch Ophthalmol 2010; 128: 663-671
• 18 Mantagos IS, Vanderveen DK, Smith LEH. Emerging treatments for retinopathy of prematurity. Semin Ophthalmol 2009; 24: 82-86
• 19 Chen J, Stahl A, Hellstrom A, Smith LE. Current update on retinopathy of prematurity: screening and treatment. Curr Opin Pediatr 2011; 23: 173-178
• 20 Mintz-Hittner HA, Kuffel Jr RR. Intravitreal injection of bevacizumab (Avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II. Retina 2008; 28: 831-838
• 21 Mintz-Hittner HA, Kennedy KA, Chuang AZ ; BEAT-ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 2011; 364: 603-615
• 22 Moshfeghi DM, Berrocal AM. Retinopathy of prematurity in the time of bevacizumab: incorporating the BEAT-ROP results into clinical practice. Ophthalmology 2011; 118: 1227-1228
• 23 Raizada S, Kandari JA, Sabti KA. Will the BEAT-ROP study results really beat ROP?. Invest Ophthalmol Vis Sci 2011; 52: 9288-9289
• 24 Hiraoka M, Berinstein DM, Trese MT, Shastry BS. Insertion and deletion mutations in the dinucleotide repeat region of the Norrie disease gene in patients with advanced retinopathy of prematurity. J Hum Genet 2001; 46: 178-181
• 25 Ells A, Guernsey DL, Wallace K , et al. Severe retinopathy of prematurity associated with FZD4 mutations. Ophthalmic Genet 2010; 31: 37-43
• 26 Shastry BS. Genetic susceptibility to advanced retinopathy of prematurity (ROP). J Biomed Sci 2010; 17: 69
• 27 Fang PC, Kuo HK, Ko TY, Chen CC, Hwang KP, Chung MY. Retinopathy of prematurity in larger preterm infants. Am J Perinatol 2006; 23: 273-277